Literature DB >> 25323833

Clinical utility of the normalized apparent diffusion coefficient for preoperative evaluation of the aggressiveness of prostate cancer.

Ryo Itatani1, Tomohiro Namimoto, Akira Yoshimura, Kazuhiro Katahira, Seiichiro Noda, Nobuyuki Toyonari, Kosuke Kitani, Yasuyuki Hamada, Mitsuhiko Kitaoka, Yasuyuki Yamashita.   

Abstract

PURPOSE: Normalization of the apparent diffusion coefficient (ADC) may overcome ADC variability attributable to different patient and/or technical factors. The purpose of this study was to compare the efficacy of ADC and the normalized ADC (nADC) for differentiating between prostate cancer with a Gleason score (GS) = 6 and GS > 6 and to identify an optimum reference for nADC calculations.
MATERIALS AND METHODS: Our study population comprised 58 patients who underwent diffusion-weighted MRI followed by radical prostatectomy. The nADC of the prostate cancer was calculated as ADC (cancer)/ADC (reference) by using the obturator internus muscle, urine in the bladder, and a 20-ml saline bottle placed on the groin as references. We performed receiver operating characteristic (ROC) analysis to identify the optimum reference for nADC calculations.
RESULTS: To differentiate between GS = 6 and GS > 6 prostate cancer, the area under the ROC curve of the nADC obtained with a saline bottle as reference was best (0.85) and significantly better than the area under the ADC ROC curve (0.71).
CONCLUSIONS: nADC is superior to ADC for estimating the aggressiveness of prostate cancer. It is a noninvasive technique that aids in the selection of appropriate treatments.

Entities:  

Mesh:

Year:  2014        PMID: 25323833     DOI: 10.1007/s11604-014-0367-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  33 in total

1.  High-b-value diffusion-weighted MR imaging of adult brain: image contrast and apparent diffusion coefficient map features.

Authors:  M C DeLano; T G Cooper; J E Siebert; M J Potchen; K Kuppusamy
Journal:  AJNR Am J Neuroradiol       Date:  2000 Nov-Dec       Impact factor: 3.825

2.  Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen.

Authors:  Adam C Braithwaite; Brian M Dale; Daniel T Boll; Elmar M Merkle
Journal:  Radiology       Date:  2008-12-18       Impact factor: 11.105

3.  Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm²) and standard high b-value (1000 s/mm²).

Authors:  Kazuhiro Kitajima; Satoru Takahashi; Yoshiko Ueno; Takeshi Yoshikawa; Yoshiharu Ohno; Makoto Obara; Hideaki Miyake; Masato Fujisawa; Kazuro Sugimura
Journal:  J Magn Reson Imaging       Date:  2012-02-27       Impact factor: 4.813

4.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2.

Authors:  Chan Kyo Kim; Byung Kwan Park; Bohyun Kim
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

5.  Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience.

Authors:  Harriet C Thoeny; Frederik De Keyzer; Raymond H Oyen; Ronald R Peeters
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

6.  Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Authors:  Joonmi Oh; Roland G Henry; Andrea Pirzkall; Ying Lu; Xiaojuan Li; Isabelle Catalaa; Susan Chang; William P Dillon; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2004-05       Impact factor: 4.813

7.  Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue.

Authors:  Keyanoosh Hosseinzadeh; Samuel David Schwarz
Journal:  J Magn Reson Imaging       Date:  2004-10       Impact factor: 4.813

8.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

Authors:  Dow-Mu Koh; Matthew Blackledge; David J Collins; Anwar R Padhani; Toni Wallace; Benjamin Wilton; N Jane Taylor; J James Stirling; Rajesh Sinha; Pat Walicke; Martin O Leach; Ian Judson; Paul Nathan
Journal:  Eur Radiol       Date:  2009-06-23       Impact factor: 5.315

9.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  3 in total

1.  Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.

Authors:  Tan B Nguyen; Alexander Ushinsky; Albert Yang; Michael Nguyentat; Sara Fardin; Edward Uchio; Chandana Lall; Thomas Lee; Roozbeh Houshyar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

2.  Apparent diffusion coefficient normalization of normal liver: Will it improve the reproducibility of diffusion-weighted imaging at different MR scanners as a new biomarker?

Authors:  Jie Zhu; Jie Zhang; Jia-Yin Gao; Jin-Ning Li; Da-Wei Yang; Min Chen; Cheng Zhou; Zheng-Han Yang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  Do the variations in ROI placement technique have influence for prostate ADC measurements?

Authors:  Yoshiko Ueno; Tsutomu Tamada; Keitaro Sofue; Yasuyo Urase; Nobuyuki Hinata; Masato Fujisawa; Takamichi Murakami
Journal:  Acta Radiol Open       Date:  2022-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.